Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Add To Watchlist

Recent & Breaking News (NDAQ:DCTH)

Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023

PR Newswire March 27, 2023

Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch

PR Newswire February 16, 2023

Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit

PR Newswire February 14, 2023

Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16

PR Newswire January 30, 2023

Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology

PR Newswire January 17, 2023

Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)

PR Newswire December 16, 2022

Delcath Systems Closes Private Placement of $6.2 Million

PR Newswire December 13, 2022

Delcath Systems Announces Private Placement of $6.2 Million

PR Newswire December 8, 2022

Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

PR Newswire December 5, 2022

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire November 9, 2022

Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update

PR Newswire November 8, 2022

Delcath Systems to Host Third Quarter 2022 Results

PR Newswire October 24, 2022

Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022

PR Newswire September 1, 2022

Delcath Systems Reports Second Quarter 2022 Results and Provides Business Update

PR Newswire August 8, 2022

Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

PR Newswire August 5, 2022

Delcath Systems to Host Second Quarter 2022 Results

PR Newswire July 27, 2022

Delcath Systems Closes Private Placement of $5.0 Million

PR Newswire July 20, 2022

Delcath Systems Announces Private Placement of $5.0 Million

PR Newswire July 18, 2022

Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting

GlobeNewswire June 6, 2022

Delcath Systems Reports First Quarter 2022 Results and Provides Business Update

GlobeNewswire May 10, 2022